01 / DESIGN
What was studied?
The trial randomized 529 participants with heart failure with preserved ejection fraction and obesity to semaglutide or placebo for 52 weeks.
02 / FINDINGS
What did the researchers report?
The semaglutide group had greater improvement in a heart-failure symptom score, greater weight reduction and better six-minute walk performance than the placebo group.
03 / LIMITS
How should it be interpreted?
The primary endpoints were symptoms and weight, not proof of longer survival. Results in this particular heart-failure population cannot be extended automatically to other forms of heart failure or to healthy individuals.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.